Ma P, Zhang Z, Qian M, Jiang H, Zhao Y, Shan Q
Ther Adv Med Oncol. 2024; 16:17588359241292227.
PMID: 39529892
PMC: 11552054.
DOI: 10.1177/17588359241292227.
Hilser T, Darr C, Niegisch G, Schnabel M, Foller S, Hauser L
Cancers (Basel). 2024; 16(17).
PMID: 39272856
PMC: 11393955.
DOI: 10.3390/cancers16172998.
Todorovic D, Stojanovic B, Filip M, dordevic D, Stankovic M, Jovanovic I
Diagnostics (Basel). 2024; 14(7).
PMID: 38611674
PMC: 11011689.
DOI: 10.3390/diagnostics14070761.
Ali A, Adams D, Kasabwala D, Tang C, Ho T
Sci Rep. 2023; 13(1):10544.
PMID: 37386095
PMC: 10310728.
DOI: 10.1038/s41598-023-37671-3.
Ma X, Fang W, Wang D, Shao N, Chen J, Nie T
Pharmaceutics. 2023; 15(4).
PMID: 37111692
PMC: 10145863.
DOI: 10.3390/pharmaceutics15041207.
Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
Tan D, Miao D, Zhao C, Shi J, Lv Q, Xiong Z
BMC Cancer. 2023; 23(1):264.
PMID: 36949462
PMC: 10035225.
DOI: 10.1186/s12885-023-10740-6.
Systematic Construction and Validation of a Novel Macrophage Differentiation-Associated Prognostic Model for Clear Cell Renal Cell Carcinoma.
Liu C, Zhang X, Hu C, Liang X, Cao X, Wang D
Front Genet. 2022; 13:877656.
PMID: 35774505
PMC: 9237391.
DOI: 10.3389/fgene.2022.877656.
Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer.
Hayashi F, Shigemura K, Maeda K, Hiraoka A, Maeshige N, Ooya T
J Clin Med. 2022; 11(9).
PMID: 35566574
PMC: 9104877.
DOI: 10.3390/jcm11092448.
Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian....
Song L, Liu S, Zhao S
Bioengineered. 2022; 13(4):11240-11257.
PMID: 35485300
PMC: 9208494.
DOI: 10.1080/21655979.2022.2064205.
CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC.
Sanders C, Hamad A, Ng S, Hosni R, Ellinger J, Klumper N
Cancers (Basel). 2022; 14(6).
PMID: 35326691
PMC: 8946052.
DOI: 10.3390/cancers14061541.
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment.
Hu H, Chen Y, Tan S, Wu S, Huang Y, Fu S
Front Immunol. 2022; 13:802846.
PMID: 35281003
PMC: 8905241.
DOI: 10.3389/fimmu.2022.802846.
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W, Ren D, Xiong W, Jin X, Zhu L
J Exp Clin Cancer Res. 2022; 41(1):38.
PMID: 35081978
PMC: 8790872.
DOI: 10.1186/s13046-022-02253-0.
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D, Motzer R, Suarez C, Blum S, Ejzykowicz F, Hamilton M
Lancet Oncol. 2022; 23(2):292-303.
PMID: 35032437
PMC: 9479564.
DOI: 10.1016/S1470-2045(21)00693-8.
Identification of a Six-Gene Prognostic Signature Characterized by Tumor Microenvironment Immune Profiles in Clear Cell Renal Cell Carcinoma.
Zhang L, Li J, Zhang M, Wang L, Yang T, Shao Q
Front Genet. 2021; 12:722421.
PMID: 34868201
PMC: 8637193.
DOI: 10.3389/fgene.2021.722421.
Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody.
Huang J, Wang Y, Zhang H, Hu X, Wang P, Cai W
Cancer Commun (Lond). 2021; 41(10):1071-1074.
PMID: 34363742
PMC: 8504141.
DOI: 10.1002/cac2.12206.
RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway.
Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X
Adv Sci (Weinh). 2021; 8(18):e2100881.
PMID: 34319001
PMC: 8456228.
DOI: 10.1002/advs.202100881.
Ubiquitin Modification Patterns of Clear Cell Renal Cell Carcinoma and the Ubiquitin Score to Aid Immunotherapy and Targeted Therapy.
Zhou P, Lu Y, Xun Y, Xu J, Liu C, Xia Q
Front Cell Dev Biol. 2021; 9:659294.
PMID: 34055790
PMC: 8158301.
DOI: 10.3389/fcell.2021.659294.
A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?.
Giunchi F, Franceschini T, Fiorentino M
Transl Androl Urol. 2021; 10(3):1553-1561.
PMID: 33850789
PMC: 8039592.
DOI: 10.21037/tau-20-1185.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B
N Engl J Med. 2021; 384(9):829-841.
PMID: 33657295
PMC: 8436591.
DOI: 10.1056/NEJMoa2026982.
Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.
Li S, Zhang Q, Hong Y
Technol Cancer Res Treat. 2020; 19:1533033820980116.
PMID: 33287656
PMC: 7727091.
DOI: 10.1177/1533033820980116.